MTND4P28: A Potential Drug Target and Biomarker (G100873249)

Target Name: MTND4P28

NCBI ID: G100873249

MTND4P28

Other Name(s): MT-ND4 pseudogene 28

MTND4P28: A Potential Drug Target and Biomarker

Mitochondrial dysfunction (MCD) is a condition characterized by the progressive loss of mitochondrial organelles, leading to impaired energy metabolism and increased risk of various diseases, including neurodegenerative disorders, cardiomyopathy, and cancer. The mitochondria are responsible for producing energy in the form of ATP, which is the body's primary energy currency. Therefore, any disorder that affects the function of mitochondria can have a significant impact on an individual's health and well-being.

MTND4P28 is a protein that is expressed in the mitochondria and has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and cardiomyopathy. The protein is named after its position in the protein sequence, with MTND4 representing the mitochondrial protein and P28 representing its position in the sequence.

TheMTND4P28 protein is a subunit of the mitochondrial protein complex P28, which is involved in the regulation of mitochondrial function and structure. P28 is a complex that contains multiple subunits, including the alpha subunit (A), the beta subunit (B), and the gamma subunit (G). TheMTND4P28 protein is a representative subunit of P28 and is involved in the regulation of mitochondrial function, such as the expression of genes involved in energy metabolism and stress response.

Studies have suggested that MTND4P28 may be a drug target for various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroinclusions, which are hallmarks of the disorders.

In addition to its potential role as a drug target, MTND4P28 has also been identified as a potential biomarker for neurodegenerative disorders. The loss of mitochondrial function in these disorders can be detected using various techniques, including Western blotting, immunofluorescence, and biochemical assays. However, identifying a potential drug target and biomarker can provide valuable insights into the underlying mechanisms of a disease and help to identify new treatments.

MTND4P28 has been shown to be involved in the regulation of mitochondrial function and metabolism, which is critical for the proper functioning of brain cells. Studies have suggested that MTND4P28 may be involved in the regulation of the expression of genes involved in energy metabolism and stress response, such as the genes involved in the production of reactive oxygen species (ROS) and the detoxification of reactive oxygen species.

In addition to its role in energy metabolism, MTND4P28 may also be involved in the regulation of the immune response and inflammation. Studies have suggested that MTND4P28 may be involved in the regulation of the production of pro-inflammatory cytokines, such as interleukin-1 (IL-1), and that this may contribute to the development of autoimmune disorders.

Furthermore, MTND4P28 has also been shown to be involved in the regulation of cellular stress, which is a critical aspect of the immune response and inflammation. Studies have suggested that MTND4P28 may be involved in the regulation of the stress response and the detoxification of cellular stress, which are critical for the proper functioning of brain cells.

In conclusion, MTND4P28 is a protein that is expressed in the mitochondria and has been identified as a potential drug target and biomarker for various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The protein is involved in the regulation of mitochondrial function and metabolism, energy metabolism, stress response, and the immune response, which are critical for the proper functioning of brain cells. Further research is needed to fully understand the role of MTND4P28 in

Protein Name: MT-ND4 Pseudogene 28

The "MTND4P28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTND4P28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets